Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion

VRTX posted Q3 2026 revenue of $3.44 billion, beating estimates by 1.2%, but an earnings miss at $4.76 per share clouds the print. Revenue grew 12% year over year, driven by the cystic fibrosis franchise and newer therapies CASGEVY and JOURNAVX.

The miss traces to higher operating expenses and acquisition costs tied to the Crinetics Pharmaceuticals deal. That makes the shortfall look more like a deal-related spending hit than a demand problem, though that is interpretation, not a company statement.

Management raised full-year revenue guidance to a range of $13.15 billion to $13.25 billion. Lifting the outlook alongside a top-line beat signals confidence in the commercial base, and the two newer products are now contributing meaningfully to growth.

The next hard catalyst is an FDA decision on povetacicept for kidney disease, due November 30, 2026. A binary regulatory outcome like this can move the stock independent of quarterly numbers.